Turnstone Biologics Corp. is a clinical-stage biotechnology company. The Company is focused on developing new medicines to treat and cure patients with solid tumors. It is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. It is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. It is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patientâs tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
TURNSTONE BIOLOGICS CORP. 